Moderna opposes GSK bids to dismiss counterclaims in US vaccine patent suits
MLex Summary: Moderna filed answering briefs to GlaxoSmithKline motions to dismiss counterclaims in the company’s two patent infringement suits over mRNA technology in Covid and RSV vaccines. GSK moved to dismiss...To view the full article, register now.
Already a subscriber? Click here to view full article